GlassScriptPhysician profile
Michele L Cleary
NPI 1811780273
$1,301.22
in general payments reported to CMS, 2019-2025
20 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $220.23 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Janssen Biotech, INC. | $143.02 | 2025 | Tecvayli, Talvey, Darzalex |
| Abbvie INC. | $125.78 | 2025 | |
| Daiichi Sankyo INC. | $125.00 | 2025 | Datroway |
| Novartis Pharmaceuticals Corporation | $107.93 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $94.03 | 2025 | Reblozyl |
| Genentech USA, INC. | $70.92 | 2025 | Venclexta, Tecentriq, Polivy |
| Caris Mpi, INC. | $66.97 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $46.93 | 2025 | |
| Pharmacosmos Therapeutics INC. | $34.25 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $34.14 | 2025 | Fruzaqla |
| Glaxosmithkline, LLC. | $34.10 | 2025 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $30.34 | 2025 | Imfinzi |
| Taiho Oncology, INC. | $29.50 | 2025 | |
| Pfizer INC. | $28.24 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $26.02 | 2025 | Lynozyfic |
| Spectrum Pharmaceuticals INC. | $23.81 | 2025 | Rolvedon |
| Accord Healthcare, INC. | $21.03 | 2025 | |
| Puma Biotechnology, INC. | $20.24 | 2025 | |
| Beone Medicines USA, INC. | $18.74 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Cleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.